| 发明名称 | Methods for treatment with bucindolol based on genetic targeting | ||
| 摘要 | The present invention concerns the use of methods for evaluating bucindolol treatment for a patient, particularly one with heart failure. It concerns methods for determining whether to administer or prescribe bucindolol to a patient based on whether the patient is homozygous for the Arg 389 polymorphism in the β1-adrenergic receptor (AR). | ||
| 申请公布号 | US8916603(B2) | 申请公布日期 | 2014.12.23 |
| 申请号 | US201113309114 | 申请日期 | 2011.12.01 |
| 申请人 | The Regents of the University of Colorado, A Body Corporate | 发明人 | Liggett Stephen B.;Bristow Michael |
| 分类号 | A61K31/405;A61K47/00;A61P43/00;C12Q1/68;G01N33/53;C07H21/02;C07H21/04 | 主分类号 | A61K31/405 |
| 代理机构 | Fulbright & Jaworski LLP | 代理人 | Fulbright & Jaworski LLP |
| 主权项 | 1. A method for treating heart failure, cardiac arrhythmia, or hypertension in a human patient with bucindolol comprising administering bucindolol to a patient after a sample from the patient has been genotyped and determined to be homozygous for a cytosine at position 1165 in the nucleotide coding sequence of β1AR gene. | ||
| 地址 | Boulder CO US | ||